Loading organizations...
Repositive is a technology company.
Repositive provides a platform with bioinformatics tools for accessing and sharing human genomic data. The company curates and standardizes metadata from over 5,300 preclinical models, creating an extensive directory for cancer research. This platform assists researchers in discovering and utilizing consented genomic data and models, aiming to accelerate precision cancer therapy development.
Founded by CEO Fiona Nielsen and co-founder/CTO Adrian Alexa, Repositive addressed the need to streamline genomic data access. Nielsen, a bioinformatics scientist with software development expertise, built the data sharing solution. Incorporated in 2013, the company was established on the insight that improved research data access significantly advances therapeutic discovery.
Repositive serves biopharma, contract research organizations, and academic researchers requiring genomic and preclinical cancer model data. The platform helps users efficiently find, access, and share vital research assets. Its vision is to accelerate scientific discoveries into clinical applications, particularly in precision oncology, through a more accessible data ecosystem.
Repositive has raised $4.2M across 4 funding rounds.
Repositive has raised $4.2M in total across 4 funding rounds.
Repositive is a UK-based technology company specializing in genomic data access and collaboration, primarily serving researchers, pharmaceutical, biotech, and academic sectors. Their platform simplifies the discovery and secure sharing of human genomic data from multiple global sources, addressing the common problem of time-consuming and complex data access in genetic research. By enabling easier data findability and fostering a collaborative community, Repositive accelerates genomic research and drug development, particularly in oncology. The company has demonstrated growth momentum with over one million datasets on its platform and expanding global users, supported by recent Series A funding of £2.5 million to enhance commercial offerings and data sources[2][3][5].
Founded in 2014 as a spin-out from the charity DNAdigest, Repositive emerged to tackle the significant delays in genomic research caused by difficulties in locating and accessing relevant DNA data repositories. The founding team includes CEO Fiona Nielsen, a bioinformatics scientist with extensive experience in genome analysis and software development, alongside co-founders with backgrounds in AI, genomics, and health technology. The idea originated from recognizing the inefficiencies in genomic data sharing and access, leading to the creation of a platform that encourages data discoverability and collaboration while respecting privacy concerns. Early traction included graduating from Cambridge Social Ventures and securing partnerships with leading genetic research and pharma companies, particularly in oncology[2][3][4][5].
Repositive rides the growing trend of precision medicine and data-driven genomic research, where efficient access to high-quality genomic data is critical. The timing is favorable due to increasing global investments in genomics, the rise of big data analytics in healthcare, and the urgent need for accelerated drug development, especially in oncology. Market forces such as the expansion of biopharma R&D and regulatory emphasis on data sharing amplify Repositive’s relevance. By enabling streamlined data access and fostering collaboration, Repositive influences the broader ecosystem by reducing research bottlenecks and supporting translational success from preclinical studies to clinical trials[2][5][6].
Looking ahead, Repositive is poised to expand its commercial offerings with premium platform features and broaden its data source integrations, supported by recent funding rounds. Trends shaping its journey include advances in AI-driven genomic analysis, increasing demand for personalized medicine, and growing emphasis on collaborative research infrastructures. As the platform scales, its influence may evolve from a data access facilitator to a central hub for genomic research innovation, potentially integrating more advanced analytics and expanding into new therapeutic areas beyond oncology. This trajectory aligns with its mission to accelerate genomic research and drug development by making data more accessible and actionable[2][3][5].
Repositive has raised $4.2M in total across 4 funding rounds.
Repositive's investors include Will Martin, Jonathan Milner, Pierre Socha, Lennart Hergel, Force Over Mass, Cambridge Angels, ClearlySo, Seedcamp, Innovate UK, Julie Devonshire OBE.
Repositive has raised $4.2M across 4 funding rounds. Most recently, it raised $3.0M Series A in April 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2017 | $3.0M Series A | Will Martin, Jonathan Milner, Pierre Socha, Lennart Hergel, Force Over Mass | |
| Feb 2, 2016 | $720K Seed | Jonathan Milner, Pierre Socha, Cambridge Angels, ClearlySo, Seedcamp | |
| Jul 21, 2015 | $78K Grant | Innovate UK | |
| Mar 26, 2015 | $450K Grant / Seed | Julie Devonshire OBE |